AR070828A1 - Derivados de azetidina y ciclobutano como inhibidores de jak - Google Patents

Derivados de azetidina y ciclobutano como inhibidores de jak

Info

Publication number
AR070828A1
AR070828A1 ARP090100869A ARP090100869A AR070828A1 AR 070828 A1 AR070828 A1 AR 070828A1 AR P090100869 A ARP090100869 A AR P090100869A AR P090100869 A ARP090100869 A AR P090100869A AR 070828 A1 AR070828 A1 AR 070828A1
Authority
AR
Argentina
Prior art keywords
alkyl
phenyl
heteroaryl
optionally substituted
azetidine
Prior art date
Application number
ARP090100869A
Other languages
English (en)
Spanish (es)
Inventor
James D Rodgers
David Meloni
Stacey Shepard
Yun-Long Li
Pingli Liu
Michael Xia
Jiacheng Zhou
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591836&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR070828(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of AR070828A1 publication Critical patent/AR070828A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60Q—ARRANGEMENT OF SIGNALLING OR LIGHTING DEVICES, THE MOUNTING OR SUPPORTING THEREOF OR CIRCUITS THEREFOR, FOR VEHICLES IN GENERAL
    • B60Q3/00—Arrangement of lighting devices for vehicle interiors; Lighting devices specially adapted for vehicle interiors
    • B60Q3/70—Arrangement of lighting devices for vehicle interiors; Lighting devices specially adapted for vehicle interiors characterised by the purpose
    • B60Q3/76—Arrangement of lighting devices for vehicle interiors; Lighting devices specially adapted for vehicle interiors characterised by the purpose for spotlighting, e.g. reading lamps
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60Q—ARRANGEMENT OF SIGNALLING OR LIGHTING DEVICES, THE MOUNTING OR SUPPORTING THEREOF OR CIRCUITS THEREFOR, FOR VEHICLES IN GENERAL
    • B60Q3/00—Arrangement of lighting devices for vehicle interiors; Lighting devices specially adapted for vehicle interiors
    • B60Q3/80—Circuits; Control arrangements
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S362/00—Illumination
    • Y10S362/80—Light emitting diode
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S362/00—Illumination
    • Y10S362/802—Position or condition responsive switch

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Mechanical Engineering (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP090100869A 2008-03-11 2009-03-11 Derivados de azetidina y ciclobutano como inhibidores de jak AR070828A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3566208P 2008-03-11 2008-03-11
US14498209P 2009-01-15 2009-01-15

Publications (1)

Publication Number Publication Date
AR070828A1 true AR070828A1 (es) 2010-05-05

Family

ID=40591836

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100869A AR070828A1 (es) 2008-03-11 2009-03-11 Derivados de azetidina y ciclobutano como inhibidores de jak

Country Status (43)

Country Link
US (3) US8158616B2 (Direct)
EP (1) EP2288610B8 (Direct)
JP (2) JP5275371B2 (Direct)
KR (2) KR20120108042A (Direct)
CN (2) CN102026999B (Direct)
AR (1) AR070828A1 (Direct)
AU (1) AU2009223640B2 (Direct)
BR (1) BRPI0909040B8 (Direct)
CA (1) CA2718271C (Direct)
CL (1) CL2009000576A1 (Direct)
CO (1) CO6290658A2 (Direct)
CY (2) CY1118176T1 (Direct)
DK (1) DK2288610T3 (Direct)
DO (2) DOP2010000270A (Direct)
EA (1) EA017218B1 (Direct)
EC (1) ECSP10010475A (Direct)
ES (1) ES2602577T3 (Direct)
HN (1) HN2010001761A (Direct)
HR (1) HRP20161390T1 (Direct)
HU (2) HUE029767T2 (Direct)
IL (1) IL208023A (Direct)
LT (2) LT2288610T (Direct)
LU (1) LUC00027I2 (Direct)
MA (1) MA32219B1 (Direct)
MX (1) MX2010010012A (Direct)
MY (1) MY165582A (Direct)
NL (1) NL300886I2 (Direct)
NO (1) NO2017033I1 (Direct)
NZ (1) NZ587928A (Direct)
PA (1) PA8819201A1 (Direct)
PE (2) PE20140099A1 (Direct)
PL (1) PL2288610T3 (Direct)
PT (1) PT2288610T (Direct)
RS (1) RS55263B1 (Direct)
SG (1) SG191660A1 (Direct)
SI (1) SI2288610T1 (Direct)
SV (1) SV2010003662A (Direct)
TN (1) TN2010000415A1 (Direct)
TW (1) TWI444382B (Direct)
UA (1) UA101493C2 (Direct)
UY (1) UY31705A1 (Direct)
WO (1) WO2009114512A1 (Direct)
ZA (1) ZA201006000B (Direct)

Families Citing this family (308)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060106020A1 (en) * 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
EP3184526B1 (en) 2005-12-13 2018-10-03 Incyte Holdings Corporation Pyrrolo[2,3-d]pyrimidine derivatives as janus kinase inhibitor
ES2415863T3 (es) * 2006-12-22 2013-07-29 Incyte Corporation Heterociclos sustituidos como inhibidores de Janus Quinasas
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
MX342814B (es) 2007-06-13 2016-10-13 Incyte Holdings Corp Sales de inhibidor de janus cinasa (r)-3-(4-7h-pirrolo[2,3-d]pirim idin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanitrilo.
EP2220068B1 (en) * 2007-11-16 2016-01-27 Incyte Holdings Corporation 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
CN104387382A (zh) 2008-03-24 2015-03-04 æą…èżȘç»Žæ–°æŠ€æœŻć…Źćž 搥敶ćč¶[3,4-b]ćČ據撌ćș”甚æ–čæł•
WO2009155551A1 (en) * 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine jak inhibitor compounds and methods
MX336271B (es) * 2008-06-20 2016-01-13 Genentech Inc Compuestos de triazolopiridina inhibidores de jak y los metodos.
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composiciĂłn que lo comprende para el tratamiento del ojo seco.
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp Ű·Ű±Ù‚ Ù„Ű§Ű”Ù„Ű§Ű­ Ù…Ű«ŰšŰ·Ű§ŰȘ Ű§Ù†ŰČيم jak و Ű§Ù„Ù…Ű±ÙƒŰšŰ§ŰȘ Ű§Ù„ÙˆŰłÙŠŰ·Ű© Ű§Ù„Ù…ŰȘŰčÙ„Ù‚Ű© ŰšÙ‡
SG10201402492TA (en) 2009-05-22 2014-08-28 Incyte Corp Use of jak inhibitors 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile
MX2011012353A (es) 2009-05-22 2011-12-14 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus.
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
JP5946768B2 (ja) * 2009-10-09 2016-07-06 ă‚€ăƒłă‚”ă‚€ăƒˆăƒ»ăƒ›ăƒŒăƒ«ăƒ‡ă‚Łăƒłă‚°ă‚čăƒ»ă‚łăƒŒăƒăƒŹă‚€ă‚·ăƒ§ăƒłïŒ©ïœŽïœƒïœ™ïœ”ïœ…  ïŒŁïœïœ’ïœïœïœ’ïœïœ”ïœ‰ïœïœŽ ïŒ“âˆ’ïŒˆïŒ”âˆ’ïŒˆïŒ—ïŒšâˆ’ăƒ”ăƒ­ăƒ­ïŒ»ïŒ’ïŒŒïŒ“âˆ’ïœ„ïŒœăƒ”ăƒȘăƒŸă‚žăƒłâˆ’ïŒ”âˆ’ă‚€ăƒ«ïŒ‰âˆ’ïŒ‘ïŒšâˆ’ăƒ”ăƒ©ă‚ŸăƒŒăƒ«âˆ’ïŒ‘âˆ’ă‚€ăƒ«ïŒ‰âˆ’ïŒ“âˆ’ă‚·ă‚Żăƒ­ăƒšăƒłăƒăƒ«ăƒ—ăƒ­ăƒ‘ăƒłăƒ‹ăƒˆăƒȘăƒ«ăźăƒ’ăƒ‰ăƒ­ă‚­ă‚·ăƒ«ă€ă‚±ăƒˆćŠăłă‚°ăƒ«ă‚Żăƒ­ăƒ‹ăƒ‰èȘ˜ć°Žäœ“
WO2011103423A1 (en) * 2010-02-18 2011-08-25 Incyte Corporation Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
AU2015205858B2 (en) * 2010-03-10 2017-04-13 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
TWI643857B (zh) * 2010-03-10 2018-12-11 è‹±ćĄžç‰č慬揾 䜜ç‚șïœŠïœïœ‹ïŒ‘æŠ‘ćˆ¶ćŠ‘äč‹ć“Œć•¶--ćŸș侉äșžç”ČäșžèƒșèĄç”Ÿç‰©
CN102985424B (zh) 2010-04-14 2015-03-11 é˜”ćˆ—ç”Ÿç‰©ćˆ¶èŻć…Źćž 5,7-ć–ä»Łçš„-ć’Ș攑ćč¶[1,2-c]ć˜§ć•¶
HUE029035T2 (en) 2010-05-21 2017-01-30 Incyte Holdings Corp Topical formulation for a jak inhibitor
UA113156C2 (xx) * 2010-11-19 2016-12-26 ĐŠĐžĐșĐ»ĐŸĐ±ŃƒŃ‚ĐžĐ»Đ·Đ°ĐŒŃ–Ń‰Đ”ĐœŃ– ĐżĐŸŃ…Ń–ĐŽĐœŃ– ĐżŃ–Ń€ĐŸĐ»ĐŸĐżŃ–Ń€ĐžĐŽĐžĐœŃƒ Đč ĐżŃ–Ń€ĐŸĐ»ĐŸĐżŃ–Ń€ĐžĐŒŃ–ĐŽĐžĐœŃƒ яĐș Ń–ĐœĐłŃ–Đ±Ń–Ń‚ĐŸŃ€Đž jak
EA036970B1 (ru) * 2010-11-19 2021-01-21 Đ˜ĐœŃĐ°Đčт Đ„ĐŸĐ»ĐŽĐžĐœĐłŃ ĐšĐŸŃ€ĐżĐŸŃ€Đ”ĐčŃˆĐœ ĐŸŃ€ĐžĐŒĐ”ĐœĐ”ĐœĐžĐ” {1-{1-[3-Ń„Ń‚ĐŸŃ€-2-(Ń‚Ń€ĐžŃ„Ń‚ĐŸĐŒĐ”Ń‚ĐžĐ»)ĐžĐ·ĐŸĐœĐžĐșĐŸŃ‚ĐžĐœĐŸĐžĐ»] ĐżĐžĐżĐ”Ń€ĐžĐŽĐžĐœ-4-Ол}-3-[4-(7h-ĐżĐžŃ€Ń€ĐŸĐ»ĐŸ[2,3-d]ĐżĐžŃ€ĐžĐŒĐžĐŽĐžĐœ-4-Ол)-1Đœ-ĐżĐžŃ€Đ°Đ·ĐŸĐ»-1-Ол]Đ°Đ·Đ”Ń‚ĐžĐŽĐžĐœ-3-Ол}Đ°Ń†Đ”Ń‚ĐŸĐœĐžŃ‚Ń€ĐžĐ»Đ° ĐŽĐ»Ń Đ»Đ”Ń‡Đ”ĐœĐžŃ Đ·Đ°Đ±ĐŸĐ»Đ”ĐČĐ°ĐœĐžĐč, сĐČŃĐ·Đ°ĐœĐœŃ‹Ń… с Đ°ĐșтоĐČĐœĐŸŃŃ‚ŃŒŃŽ jak1
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
US8658686B2 (en) * 2010-12-01 2014-02-25 Nissan Chemical Industries, Ltd. Pyrazole compounds having therapeutic effect on multiple myeloma
EP2675451B9 (en) 2011-02-18 2017-07-26 Novartis Pharma AG mTOR/JAK INHIBITOR COMBINATION THERAPY
IN2013MN01699A (Direct) 2011-02-18 2015-06-12 Medivation Technologies Inc
WO2012120025A1 (en) * 2011-03-08 2012-09-13 Ge Healthcare Limited Preparation of a 1-amino-3-hydroxy-cyclobutane-1-carboxylic acid derivative
MX344479B (es) * 2011-06-20 2016-12-16 Incyte Holdings Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de cinasa janus (jak).
US9358229B2 (en) 2011-08-10 2016-06-07 Novartis Pharma Ag JAK PI3K/mTOR combination therapy
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 䜜ç‚șïœŠïœïœ‹æŠ‘ćˆ¶ćŠ‘äč‹ç’°ć·±ćŸșæ°źé›œç’°äžçƒ·èĄç”Ÿç‰©
UA111854C2 (uk) * 2011-09-07 2016-06-24 Đ†ĐœŃĐ°Đčт Đ„ĐŸĐ»ĐŽŃ–ĐœĐłŃ ĐšĐŸŃ€ĐżĐŸŃ€Đ”ĐčŃˆĐœ ĐĄĐżĐŸŃĐŸĐ±Đž і ĐżŃ€ĐŸĐŒŃ–Đ¶ĐœŃ– ŃĐżĐŸĐ»ŃƒĐșĐž ĐŽĐ»Ń ĐŸŃ‚Ń€ĐžĐŒĐ°ĐœĐœŃ Ń–ĐœĐłŃ–Đ±Ń–Ń‚ĐŸŃ€Ń–ĐČ jak
EP2758377B1 (en) * 2011-09-22 2017-08-02 Merck Sharp & Dohme Corp. Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors
EP3750544B1 (en) 2011-11-30 2025-03-05 Emory University Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
AR091079A1 (es) 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
JP6280546B2 (ja) 2012-06-26 2018-02-14 ăƒ‡ăƒ« ăƒžăƒŒ ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚ș ă‚žă‚ąăƒłăƒ’ăƒ‰ăƒ­ă‚Źăƒ©ă‚ŻăƒăƒˆăƒŒăƒ«ă€ă‚žă‚ąă‚»ăƒăƒ«ă‚žă‚ąăƒłăƒ’ăƒ‰ăƒ­ă‚Źăƒ©ă‚ŻăƒăƒˆăƒŒăƒ«ă€ă‚žăƒ–ăƒ­ăƒąă‚șăƒ«ă‚·ăƒˆăƒŒăƒ«ă€ćˆăŻă“ă‚Œă‚‰ăźéĄžäŒŒäœ“è‹„ă—ăăŻèȘ˜ć°Žäœ“ă‚’ç”šă„ăŸă€éșäŒć­ć€šćž‹ćˆăŻïœïœˆïœ‰ïŒ‘ăźèȘżçŻ€äžć…šè‹„ă—ăăŻć€‰ç•°ă‚’æœ‰ă™ă‚‹æ‚Łè€…ă«ăŠă‘ă‚‹ăƒăƒ­ă‚·ăƒłă‚­ăƒŠăƒŒă‚Œă‚€ăƒłăƒ’ăƒ“ă‚żăƒŒæŠ”æŠ—æ€§æ‚Șæ€§è…«ç˜ă‚’ć‡Šçœźă™ă‚‹ăŸă‚ăźæ–čæł•
JP6276762B2 (ja) * 2012-08-02 2018-02-07 ăƒăƒ«ăƒ“ă‚ąăƒŒăƒŽăƒ»ăƒĄăƒ‡ă‚€ă‚«ăƒ«ăƒ»ă‚”ă‚€ă‚šăƒłă‚·ăƒŒă‚șăƒ»ă‚šăƒ„ă‚»ăƒ»ă‚šăƒ«ăƒŹăƒ»ă‚šăƒ«ăƒŹ ă‚­ăƒŠăƒŒă‚Œé˜»ćźłć‰€ăšă—ăŠæŽ»æ€§ăȘçœźæ›ăƒ”ăƒ­ăƒŒăƒ«éĄž
US9540367B2 (en) * 2012-08-17 2017-01-10 Concert Pharmaceuticals, Inc. Deuterated baricitinib
SG10201703533VA (en) 2012-11-01 2017-06-29 Incyte Corp Tricyclic fused thiophene derivatives as jak inhibitors
NZ708157A (en) 2012-11-15 2019-07-26 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
CN103965114B (zh) * 2013-01-28 2016-01-06 è‹ć·žæłœç’Ÿç”Ÿç‰©ćˆ¶èŻæœ‰é™ć…Źćž æ°˜ä»Łçš„è‹ŻćŸșæ°šćŸșć˜§ć•¶ćŒ–ćˆç‰©ä»„ćŠćŒ…ć«èŻ„ćŒ–ćˆç‰©çš„èŻç‰©ç»„ćˆç‰©
PE20200298A1 (es) * 2013-03-06 2020-02-06 Incyte Holdings Corp Procesos e intermedios para hacer un inhibidor de jak
WO2014146249A1 (en) * 2013-03-19 2014-09-25 Merck Sharp & Dohme Corp. Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors
US11491154B2 (en) 2013-04-08 2022-11-08 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
FI3786162T3 (fi) * 2013-05-17 2023-10-02 Incyte Holdings Corp Bipyratsolijohdannaisia jak-inhibiittoreina
AU2014293011A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Compositions to improve the therapeutic benefit of bisantrene
CN105579032A (zh) 2013-08-07 2016-05-11 ć› è”›ç‰č慬揾 Jak1æŠ‘ćˆ¶ć‰‚çš„æŒç»­é‡Šæ”Ÿć‰‚ćž‹
WO2015026818A1 (en) 2013-08-20 2015-02-26 Incyte Corporation Survival benefit in patients with solid tumors with elevated c-reactive protein levels
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
EA201691594A1 (ru) 2014-02-13 2017-02-28 Đ˜ĐœŃĐ°Đčт ĐšĐŸŃ€ĐżĐŸŃ€Đ”ĐčŃˆĐœ ĐŠĐžĐșĐ»ĐŸĐżŃ€ĐŸĐżĐžĐ»Đ°ĐŒĐžĐœŃ‹ ĐČ ĐșачДстĐČĐ” ĐžĐœĐłĐžĐ±ĐžŃ‚ĐŸŃ€ĐŸĐČ lsd1
US9493442B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
HUE046273T2 (hu) 2014-02-13 2020-02-28 Incyte Corp Ciklopropilaminok mint LSD1 inhibitorok
CN106661039B (zh) 2014-02-28 2019-09-13 æž—äŒŻćŁ«æ‹‰ć…‹èźžç±łć…Źćž é…Șæ°šé…žè›‹ç™œèŽšæż€é…¶2(tyk2)æŠ‘ćˆ¶ć‰‚ć’Œć…¶ç”šé€”
SMT201800551T1 (it) 2014-02-28 2019-01-11 Incyte Corp Inibitori di jak1 per il trattamento di sindromi mielodisplastiche
EP3134412A1 (en) * 2014-03-28 2017-03-01 Sun Pharmaceutical Industries Limited Amorphous form of baricitinib
SG11201609016VA (en) 2014-04-30 2016-11-29 Incyte Corp Processes of preparing a jak1 inhibitor and new forms thereto
WO2015166434A1 (en) * 2014-05-01 2015-11-05 Sun Pharmaceutical Industries Limited Crystalline form of baricitinib
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 çŸŽć•†è‹±ćĄžç‰č慬揾 䜜ç‚șïœŒïœ“ïœ„ïŒ‘æŠ‘ćˆ¶ćŠ‘äč‹ć’Ș攑ćč¶ćĄć•¶ćŠć’Ș攑ćč¶ćĄć—Ș
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
WO2016024232A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
RS63364B1 (sr) 2014-08-11 2022-07-29 Acerta Pharma Bv Terapeutske kombinacije btk inhibitora, pd-1 inhibitora i/ili pd-l1 inhibitora
PL3179991T3 (pl) 2014-08-11 2022-02-14 Acerta Pharma B.V. Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2
WO2016023082A1 (en) 2014-08-12 2016-02-18 Monash University Lymph directing prodrugs
TWI679205B (zh) 2014-09-02 2019-12-11 æ—„ć•†æ—„æœŹæ–°è—„è‚Ąä»œæœ‰é™ć…Źćž 搡攑ćč¶ć™»ć”‘ćŒ–ćˆç‰©ćŠé†«è—„
CN105524067A (zh) * 2014-09-28 2016-04-27 æ±Ÿè‹æŸŻèČćčłćŒ»èŻè‚Ąä»œæœ‰é™ć…Źćž 4-ć–ä»ŁćĄć’Żćč¶[2,3-d]ć˜§ć•¶ćŒ–ćˆç‰©ćŠć…¶ç”šé€”
SMT202100301T1 (it) 2014-10-29 2021-07-12 Bicyclerd Ltd Ligandi peptidici biciclici specifici per mt1-mmp
US9873706B2 (en) 2014-12-05 2018-01-23 Sun Pharmaceutical Industries Limited Process for the preparation of baricitinib and an intermediate thereof
CN105777754B (zh) 2014-12-16 2019-07-26 挗äșŹè”›æž—æł°ćŒ»èŻæŠ€æœŻæœ‰é™ć…Źćž 搡撯ćč¶ć˜§ć•¶ćŒ–ćˆç‰©
WO2016125080A2 (en) * 2015-02-02 2016-08-11 Sun Pharmaceutical Industries Limited Process for the preparation of baricitinib and an intermediate thereof
EP3253760A4 (en) * 2015-02-02 2018-06-20 Sun Pharmaceutical Industries Limited Process for the preparation of baricitinib and an intermediate thereof
TWI744225B (zh) 2015-02-27 2021-11-01 çŸŽć•†æž—äŒŻćŁ«æ‹‰ć…‹èš±ç±łć…Źćž é…Șèƒș酞蛋癜èłȘæż€é…¶ïŒ’ïŒˆïœ”ïœ™ïœ‹ïŒ’ïŒ‰æŠ‘ćˆ¶ćŠ‘ćŠć…¶ç”šé€”
CN105924444B (zh) * 2015-03-11 2019-06-18 è‹ć·žæ™¶äș‘èŻç‰©ç§‘æŠ€è‚Ąä»œæœ‰é™ć…Źćž JakæŠ‘ćˆ¶ć‰‚çš„æ™¶ćž‹ćŠć…¶ćˆ¶ć€‡æ–čæł•
WO2016141891A1 (zh) * 2015-03-11 2016-09-15 è‹ć·žæ™¶äș‘èŻç‰©ç§‘æŠ€æœ‰é™ć…Źćž JakæŠ‘ćˆ¶ć‰‚çš„æ™¶ćž‹ćŠć…¶ćˆ¶ć€‡æ–čæł•
ES2757948T3 (es) 2015-04-03 2020-04-30 Incyte Corp Compuestos heterocĂ­clicos como inhibidores LSD1
AR104918A1 (es) * 2015-06-19 2017-08-23 Lilly Co Eli Procesos e intermediarios para la preparaciĂłn de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo
WO2017004134A1 (en) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CN110402244B (zh) 2015-08-12 2023-02-03 ć› è”›ç‰č慬揾 Lsd1æŠ‘ćˆ¶ć‰‚çš„ç›
JP6802263B2 (ja) 2015-09-02 2020-12-16 ニンバă‚č ăƒ©ă‚Żă‚·ăƒ„ăƒŸïŒŒ ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ïŒŽïœ™ïœ‹ïŒ’é˜»ćźłć‰€ăŠă‚ˆăłăăźäœżç”š
AU2016318229A1 (en) 2015-09-08 2018-03-29 Monash University Lymph directing prodrugs
US10683308B2 (en) 2015-09-11 2020-06-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
CN106554363B (zh) * 2015-09-28 2019-03-05 æ­Łć€§ć€©æ™ŽèŻäžšé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž 侀种Baricitinibäž­é—Žäœ“çš„ćˆ¶ć€‡æ–čæł•
DK3364958T3 (da) 2015-10-23 2023-04-11 Navitor Pharm Inc Modulatorer af sestrin-gator2-interaktion og anvendelser deraf
RU2601410C1 (ru) * 2015-11-13 2016-11-10 ЗАО "Đ -Đ€Đ°Ń€ĐŒ" {3-[(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АЗОЛИЛ]АЗЕбИДИН-3-ИЛ}ĐĐŠĐ•ĐąĐžĐĐ˜ĐąĐ Đ˜Đ›Đ« В КАЧЕСбВЕ ИНГИБИбОРОВ ЯНУС КИНАЗ
RU2603959C1 (ru) * 2015-11-13 2016-12-10 ЗаĐșŃ€Ń‹Ń‚ĐŸĐ” Đ°ĐșŃ†ĐžĐŸĐœĐ”Ń€ĐœĐŸĐ” ĐŸĐ±Ń‰Đ”ŃŃ‚ĐČĐŸ "Đ -Đ€Đ°Ń€ĐŒ" (ЗАО "Đ -Đ€Đ°Ń€ĐŒ") Đ”Đ˜Đ„Đ›ĐžĐ ĐĐŠĐ•ĐąĐĐą {3-[4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-ПИРАЗОЛ-1-ИЛ]-1-Đ­ĐąĐ˜Đ›ĐĄĐŁĐ›ĐŹĐ€ĐžĐĐ˜Đ›-АЗЕбИДИН-3-ИЛ}-АЩЕбОНИбРИЛА В КАЧЕСбВЕ ИНГИБИбОРА ЯНУС КИНАЗ
CN105294699B (zh) * 2015-12-04 2019-06-11 äžŠæ”·ć‹‹ć’ŒćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž ć·Žç‘žæ›żć°Œçš„ćˆ¶ć€‡æ–čæł•
DK3360878T3 (da) * 2015-12-11 2020-11-09 Sichuan Kelun Biotech Biopharmaceutica Co Ltd Azetidinderivat, fremstillingsfremgangsmÄde derfor og anvendelse deraf
WO2017106352A1 (en) 2015-12-14 2017-06-22 Raze Therapeutics, Inc. Caffeine inhibitors of mthfd2 and uses thereof
HU230805B1 (hu) * 2015-12-23 2018-06-28 Egis GyĂłgyszergyĂĄr Zrt EljĂĄrĂĄs Ă©s köztitermĂ©k baricitinib elƑállĂ­tĂĄsĂĄra
HU230931B1 (hu) * 2016-01-21 2019-04-29 Egis GyĂłgyszergyĂĄr Zrt. Baricitinib sĂłk
EP3409673B1 (en) * 2016-01-26 2021-06-16 Hangzhou Bangshun Pharmaceutical Co., Ltd. Pyrrolopyrimidine five-membered azacyclic derivative and application thereof
CN105566332B (zh) * 2016-01-29 2018-01-16 äžŠæ”·ćźŁćˆ›ç”Ÿç‰©ç§‘æŠ€æœ‰é™ć…Źćž ć·Žç‘žć…‹æ›żć°Œäž‰æ°Ÿäč™é…žç›aæ™¶ćž‹ć’Œbæ™¶ćž‹ćŠć…¶ćˆ¶ć€‡æ–čæł•
CN107573349A (zh) * 2016-02-01 2018-01-12 äžŠæ”·ćźŁćˆ›ç”Ÿç‰©ç§‘æŠ€æœ‰é™ć…Źćž ć·Žç‘žć…‹æ›żć°ŒçŁ·é…žç›hæ™¶ćž‹ćŠć…¶ćˆ¶ć€‡æ–čæł•
CN105541891B (zh) * 2016-02-04 2017-11-28 äžœć—ć€§ć­Š ć·Žç‘žæ›żć°Œçš„äž­é—Žäœ“ćŠć…¶ćˆ¶ć€‡æ–čæł•ćŠç”±èŻ„äž­é—Žäœ“ćˆ¶ć€‡ć·Žç‘žæ›żć°Œçš„æ–čæł•
TWI712604B (zh) 2016-03-01 2020-12-11 æ—„ć•†æ—„æœŹæ–°è—„è‚Ąä»œæœ‰é™ć…Źćž ć…·jakæŠ‘ćˆ¶äœœç”šäč‹ćŒ–ćˆç‰©äč‹ç”æ™¶
EP4234552A3 (en) 2016-03-09 2023-10-18 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
HUE055197T2 (hu) 2016-03-09 2021-11-29 Raze Therapeutics Inc 3-FoszfoglicerĂĄt-dehidrogenĂĄz inhibitorok Ă©s alkalmazĂĄsuk
CN107200742A (zh) * 2016-03-18 2017-09-26 çœ—æŹŁç”Ÿç‰©ç§‘æŠ€ïŒˆäžŠæ”·ïŒ‰æœ‰é™ć…Źćž äž€ç§ć·Žç‘žć…‹æ›żć°ŒçŁ·é…žç›æ™¶äœ“ćŠć…¶ćˆ¶ć€‡æ–čæł•
CN107226814A (zh) * 2016-03-23 2017-10-03 çœ—æŹŁç”Ÿç‰©ç§‘æŠ€ïŒˆäžŠæ”·ïŒ‰æœ‰é™ć…Źćž äž€ç§ć·Žç‘žć…‹æ›żć°Œäž­é—Žäœ“çš„ćˆ¶ć€‡æ–čæł•
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
CR20180553A (es) 2016-04-22 2019-02-01 Incyte Corp Formulaciones de un inhibidor de lsd1
CN107334738B (zh) * 2016-04-28 2021-02-09 ć€©æŽ„ç§‘äŒŠèŻç‰©ç ”ç©¶æœ‰é™ć…Źćž äž€ç§ć«ć·Žç‘žć…‹æ›żć°Œçš„èŻç‰©ç»„ćˆç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œç”šé€”
CN116554168B (zh) 2016-06-21 2025-09-23 X4ćˆ¶èŻæœ‰é™ć…Źćž Cxcr4æŠ‘ćˆ¶ć‰‚ćŠć…¶ç”šé€”
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
JP6994767B2 (ja) 2016-06-21 2022-01-14 スックă‚č ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚ș ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ïŒŁïœ˜ïœƒïœ’ïŒ”é˜»ćźłć‰€ăŠă‚ˆăłăăźäœżç”š
US11279699B2 (en) 2016-07-26 2022-03-22 Suzhou Longbiotech Pharmaceuticals Co., Ltd. Compound as selective JAK inhibitor, and salt and therapeutic use thereof
CN106496233B (zh) * 2016-09-26 2018-05-15 äžœć—ć€§ć­Š 搡撯ćč¶ć˜§ć•¶ç±»ćŒ–ćˆç‰©ă€ć…¶ćˆ¶ć€‡æ–čæł•ćŠć…¶ç”šé€”
IL265922B2 (en) 2016-10-14 2025-02-01 Nimbus Lakshmi Inc TYK2 inhibitors and their uses
JP7082120B2 (ja) 2016-10-21 2022-06-07 ニンバă‚č ăƒ©ă‚Żă‚·ăƒ„ăƒŸïŒŒ ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ïŒŽïœ™ïœ‹ïŒ’é˜»ćźłć‰€ăŠă‚ˆăłăăźäœżç”š
WO2018089499A1 (en) 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
CZ2016705A3 (cs) 2016-11-11 2018-05-23 Zentiva, K.S. KrystalickĂ© formy 2- [1-ethylsulfonyl-3- [4- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) pyrazol-1-yl] azetidin-3-yl] acetonitrilovĂœch solĂ­ a jejich pƙíprava
EP3327020A1 (en) 2016-11-29 2018-05-30 Sandoz Ag Citrate salts of a janus kinase (jak) inhibitor
WO2018102397A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
WO2018106636A1 (en) 2016-12-05 2018-06-14 Raze Therapeutics, Inc. Shmt inhibitors and uses thereof
RU2644155C1 (ru) * 2016-12-12 2018-02-08 ЗаĐșŃ€Ń‹Ń‚ĐŸĐ” Đ°ĐșŃ†ĐžĐŸĐœĐ”Ń€ĐœĐŸĐ” ĐŸĐ±Ń‰Đ”ŃŃ‚ĐČĐŸ "Đ -Đ€Đ°Ń€ĐŒ" (ЗАО "Đ -Đ€Đ°Ń€ĐŒ") 2-(3-(4-(7H-ĐżĐžŃ€Ń€ĐŸĐ»ĐŸ[2,3-d]ĐżĐžŃ€ĐžĐŒĐžĐŽĐžĐœ-4-Ол)-1H-ĐżĐžŃ€Đ°Đ·ĐŸĐ»-1-Ол)-1-(ŃŃ‚ĐžĐ»ŃŃƒĐ»ŃŒŃ„ĐŸĐœĐžĐ»)Đ°Đ·Đ”Ń‚ĐžĐŽĐžĐœ-3-Ол)Đ°Ń†Đ”Ń‚ĐŸĐœĐžŃ‚Ń€ĐžĐ»Đ° ĐłĐ”ĐŒĐžĐœĐ°Ń„Ń‚ĐžĐ»ĐŽĐžŃŃƒĐ»ŃŒŃ„ĐŸĐœĐ°Ń‚ ĐČ ĐșачДстĐČĐ” ĐžĐœĐłĐžĐ±ĐžŃ‚ĐŸŃ€Đ° ĐŻĐœŃƒŃ ĐșĐžĐœĐ°Đ·
CZ2016816A3 (cs) * 2016-12-21 2018-07-04 Zentiva, K.S. KrystalickĂ© formy 2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrilu s kyselinou fosforečnou a zpĆŻsob jejich pƙípravy
JP2020502238A (ja) 2016-12-23 2020-01-23 ăƒă‚€ă‚čă‚Żăƒ«ă‚ąăƒŒăƒ«ăƒ‡ă‚ŁăƒŒăƒ»ăƒȘミテッド æ–°èŠé€Łç”æ§‹é€ ă‚’æœ‰ă™ă‚‹ăƒšăƒ—ăƒăƒ‰èȘ˜ć°Žäœ“
WO2018127699A1 (en) 2017-01-06 2018-07-12 Bicyclerd Limited Compounds for treating cancer
EA039344B1 (ru) * 2017-01-19 2022-01-17 ĐĄŃƒŃ‡Đ¶ĐŸŃƒ Đ›ĐŸĐœĐłĐ±Đ°ĐčĐŸŃ‚Đ”Đș Đ€Đ°Ń€ĐŒĐ°ŃŃŒŃŽŃ‚ĐžĐșалз ĐšĐŸ., ЛтЮ. Đ“Đ”Ń‚Đ”Ń€ĐŸŃ†ĐžĐșлОчДсĐșĐŸĐ” ŃĐŸĐ”ĐŽĐžĐœĐ”ĐœĐžĐ” ĐČ ĐșачДстĐČĐ” ĐžĐœĐłĐžĐ±ĐžŃ‚ĐŸŃ€Đ° jak Đž Đ”ĐłĐŸ ŃĐŸĐ»Đž Đž тДрапДĐČтОчДсĐșĐŸĐ” ĐżŃ€ĐžĐŒĐ”ĐœĐ”ĐœĐžĐ”
CN108341820B (zh) * 2017-01-23 2020-10-16 äžŠæ”·é•żæŁźèŻäžšæœ‰é™ć…Źćž Jaké…¶æŠ‘ćˆ¶ć‰‚ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œç”šé€”
EP4338802A3 (en) 2017-03-08 2024-09-04 Takeda Pharmaceutical Company Limited Tyk2 inhibitors, uses, and methods for production thereof
EP3375778A1 (en) 2017-03-14 2018-09-19 Artax Biopharma Inc. Aryl-piperidine derivatives
EP3375784A1 (en) 2017-03-14 2018-09-19 Artax Biopharma Inc. Aza-dihydro-acridone derivatives
CN106946917B (zh) * 2017-03-20 2019-06-11 æ­ć·žç§‘ć·ąç”Ÿç‰©ç§‘æŠ€æœ‰é™ć…Źćž 侀种jakæŠ‘ćˆ¶ć‰‚ć·Žç‘žæ›żć°ŒćŠć…¶äž­é—Žäœ“çš„æ–°ćˆæˆæ–čæł•
CN107176955B (zh) * 2017-03-24 2019-04-09 捗äșŹäŒ˜ç§‘ćˆ¶èŻæœ‰é™ć…Źćž äž€ç§ć·Žç‘žæ›żć°Œçš„ćˆ¶ć€‡æ–čæł•
WO2018191146A1 (en) 2017-04-10 2018-10-18 Navitor Pharmaceuticals, Inc. Heteroaryl rheb inhibitors and uses thereof
CA3061611A1 (en) 2017-04-26 2018-11-01 Navitor Pharmaceuticals, Inc. Modulators of sestrin-gator2 interaction and uses thereof
US10857196B2 (en) 2017-04-27 2020-12-08 Bicycletx Limited Bicyclic peptide ligands and uses thereof
MX2019014054A (es) 2017-05-23 2020-02-05 Theravance Biopharma R&D Ip Llc Profarmacos de glucuronida de inhibidores de la cinasa janus.
ES2937823T3 (es) * 2017-06-07 2023-03-31 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Forma sólida del derivado de azetidina y método de preparación del mismo y uso del mismo
WO2018233437A1 (zh) * 2017-06-22 2018-12-27 è‹ć·žç§‘çżæ€ćˆ¶èŻæœ‰é™ć…Źćž ć·Žç‘žć…‹æ›żć°Œçš„æ™¶ćž‹ćŠć…¶ćˆ¶ć€‡æ–čæł•
JP7301757B2 (ja) 2017-06-26 2023-07-03 ăƒă‚€ă‚čă‚Żăƒ«ă‚ąăƒŒăƒ«ăƒ‡ă‚ŁăƒŒăƒ»ăƒȘミテッド 怜ć‡șćŻèƒœéƒšćˆ†ă‚’æŒă€äșŒç’°ćŒăƒšăƒ—ăƒăƒ‰ăƒȘă‚Źăƒłăƒ‰ăŠă‚ˆăłăăźäœżç”š
WO2019003249A1 (en) 2017-06-28 2019-01-03 Mylan Laboratories Limited POLYMORPHIC FORMS OF BARICITINIB
IL271999B2 (en) 2017-07-28 2025-06-01 Nimbus Lakshmi Inc Tyk2 inhibitors and uses thereof
ES2926195T3 (es) 2017-08-04 2022-10-24 Bicycletx Ltd Ligandos peptĂ­dicos bicĂ­clicos especĂ­ficos de CD137
WO2019034866A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
WO2019034868A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF
CA3077739A1 (en) 2017-08-29 2019-03-07 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
MX2020003190A (es) 2017-09-22 2020-11-11 Kymera Therapeutics Inc Degradadores de proteinas y usos de los mismos.
CN109651424B (zh) * 2017-10-11 2021-01-22 æ–°ć‘èŻäžšæœ‰é™ć…Źćž 侀种7-äżæŠ€ćŸș-4-(1-æ°ą-搡攑-4-ćŸș)搡撯[2,3-d]ć˜§ć•¶çš„ćˆæˆæ–čæł•
TWI834560B (zh) 2017-10-18 2024-03-01 çŸŽć•†è‹±ćĄžç‰č慬揾 䜜ç‚șPI3K-ÎłæŠ‘ćˆ¶ćŠ‘äč‹äž‰çŽšé†‡
BR112020008850A2 (pt) * 2017-11-03 2020-10-20 Aclaris Therapeutics, Inc. composto, composição farmacĂȘutica e mĂ©todo para tratar uma doença mediada por jak1 e jak3
CN113149993A (zh) * 2017-12-01 2021-07-23 挗äșŹæ™źç„șćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž 侀种搡撯ćč¶ć˜§ć•¶èĄç”Ÿçš„ćŒ–ćˆç‰©ă€èŻç‰©ç»„ćˆç‰©ä»„ćŠć…¶ç”šé€”
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
CN108129482A (zh) * 2017-12-13 2018-06-08 æ±Ÿè‹äž­é‚Šćˆ¶èŻæœ‰é™ć…Źćž äž€ç§ć·Žç‘žæ›żć°Œçš„ćˆ¶ć€‡æ–čæł•
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
WO2019126378A1 (en) 2017-12-19 2019-06-27 Ariya Therapeutics, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
TWI825046B (zh) 2017-12-19 2023-12-11 è‹±ć•†æ‹œè„żćŻæł°ć…‹æ–Żæœ‰é™ć…Źćž Epha2ç‰č甹äč‹é›™ç’°èƒœè‚œé…äœćŸș
EP3502114A1 (en) 2017-12-20 2019-06-26 Sandoz AG Co-crystal of an orally available janus kinase inhibitor
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
US10766900B2 (en) 2017-12-29 2020-09-08 Formosa Laboratories, Inc. Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof
US11485743B2 (en) 2018-01-12 2022-11-01 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
MX2020007797A (es) 2018-01-29 2020-09-18 Merck Patent Gmbh Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
AU2019211485B2 (en) 2018-01-29 2025-01-23 Merck Patent Gmbh GCN2 inhibitors and uses thereof
AR114810A1 (es) 2018-01-30 2020-10-21 Incyte Corp Procesos e intermedios para elaborar un inhibidor de jak
IL276725B2 (en) 2018-02-16 2024-09-01 Incyte Corp Jak1 pathway inhibitors for the treatment of cytokine-related disorders
WO2019162682A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
EA202091742A1 (ru) 2018-02-27 2021-02-19 АртаĐșс Đ‘ĐžĐŸŃ„Đ°Ń€ĐŒĐ° Đ˜ĐœĐș. ĐŸĐ ĐžĐ˜Đ—Đ’ĐžĐ”ĐĐ«Đ• Đ„Đ ĐžĐœĐ•ĐĐ В КАЧЕСбВЕ ИНГИБИбОРОВ ВЗАИМОДЕЙСбВИЯ TCR-Nck
CN110357887B (zh) * 2018-03-26 2022-09-16 歊汉èȘ‰ç„„ćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž ć–ä»Łçš„7H-搡撯ćč¶[2,3-d]ć˜§ć•¶èĄç”Ÿç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œç”šé€”
WO2019191679A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Biomarkers for inflammatory skin disease
JP7720697B2 (ja) 2018-03-30 2025-08-08 ă‚€ăƒłă‚”ă‚€ăƒˆăƒ»ă‚łăƒŒăƒăƒŹă‚€ă‚·ăƒ§ăƒł ïŒȘïœïœ‹é˜»ćźłć‰€ă‚’ç”šă„ă‚‹ćŒ–è†żæ€§æ±—è…ș炎ぼæȻ療
SG11202010092XA (en) 2018-04-13 2020-11-27 Incyte Corp Biomarkers for graft-versus-host disease
ES2987356T3 (es) 2018-04-24 2024-11-14 Merck Patent Gmbh Compuestos antiproliferaciĂłn y usos de los mismos
JP7479293B2 (ja) 2018-04-24 2024-05-08 ăƒăƒŒăƒ†ăƒƒă‚Żă‚č ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚ș ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ プテăƒȘă‚žăƒŽăƒłćŒ–ćˆç‰©ăŠă‚ˆăłăăźäœżç”š
CN108752254B (zh) * 2018-05-22 2021-11-02 道搈(æœćŠ)ćŒ»èŻæŠ€æœŻæœ‰é™ć…Źćž 2-[1-(äč™ćŸșçŁș酰ćŸș)-3-æ°źæ‚çŽŻäžäșšćŸș]äč™è…ˆçš„ćˆ¶ć€‡æ–čæł•
JP2021525795A (ja) * 2018-05-25 2021-09-27 ă‚«ăƒ«ăƒˆă‚č ă‚»ăƒ©ăƒ”ăƒ„ăƒŒăƒ†ă‚Łă‚Żă‚čïŒŒă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ éȘšé«„ćą—æź–æ€§è…«ç˜ă‚’æȻ療するæ–čæł•
EP3805219A4 (en) * 2018-06-06 2022-03-23 Gengle Therapeutics, Inc. PYRAZOLOPYRIMIDI DERIVATIVE, ITS USE AND PHARMACEUTICAL COMPOSITION
EP4302827A3 (en) 2018-06-15 2024-03-13 JANSSEN Pharmaceutica NV Rapamycin analogs and uses thereof
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
EP3817748A4 (en) 2018-07-06 2022-08-24 Kymera Therapeutics, Inc. TRICYCLIC CRBN LIGANDS AND USES THEREOF
EP3817822A4 (en) 2018-07-06 2022-07-27 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
WO2020051424A1 (en) 2018-09-07 2020-03-12 Pic Therapeutics Eif4e inhibitors and uses thereof
CN109146898B (zh) 2018-09-07 2020-07-24 癟ćșŠćœšçșżçœ‘ç»œæŠ€æœŻïŒˆćŒ—äșŹïŒ‰æœ‰é™ć…Źćž äž€ç§ä»żçœŸæ•°æźé‡ćąžćŒșæ–čæł•ă€èŁ…çœźä»„ćŠç»ˆç«Ż
CN109215136B (zh) 2018-09-07 2020-03-20 癟ćșŠćœšçșżçœ‘ç»œæŠ€æœŻïŒˆćŒ—äșŹïŒ‰æœ‰é™ć…Źćž äž€ç§çœŸćźžæ•°æźćąžćŒșæ–čæł•ă€èŁ…çœźä»„ćŠç»ˆç«Ż
WO2020072870A1 (en) 2018-10-05 2020-04-09 Johnson Matthey Public Limited Company Co-crystal forms of baricitinib
WO2020081508A1 (en) 2018-10-15 2020-04-23 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
TW202033198A (zh) 2018-10-17 2020-09-16 çŸŽć•†çŸŽćœ‹çŠźäŸ†ć€§è—„ć»  ä»„ć·Žç‘žć…‹æ›żć°Œ(baricitinib)æČ»ç™‚ćŽŸç™Œæ€§è†œæ±æ€§è†œçźĄç‚ŽćŠćŽŸç™Œæ€§çĄŹćŒ–æ€§è†œçźĄç‚Ž
JP2022512779A (ja) 2018-10-23 2022-02-07 ăƒă‚€ă‚čă‚Żăƒ«ăƒ†ă‚Żă‚č・ăƒȘミテッド äșŒç’°ćŒăƒšăƒ—ăƒăƒ‰ăƒȘă‚Źăƒłăƒ‰ăŠă‚ˆăłăăźäœżç”š
CA3117336A1 (en) 2018-10-24 2020-04-30 Navitor Pharmaceuticals, Inc. Polymorphs of (s)-2-amino-5,5-difluoro-4,4-dimethylpentanoic acid for use in modulating mtorc1
EP3873433A1 (en) 2018-10-31 2021-09-08 Incyte Corporation Combination therapy for treatment of hematological diseases
AU2019389174A1 (en) 2018-11-30 2021-07-01 Kymera Therapeutics, Inc. Irak degraders and uses thereof
EP3886843A4 (en) 2018-11-30 2022-08-31 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
CN111320633B (zh) * 2018-12-14 2022-09-27 äž­ć›œćŒ»èŻç ”ç©¶ćŒ€ć‘äž­ćżƒæœ‰é™ć…Źćž 搡撯/ć’Ș攑ćč¶ć…­ć…ƒæ‚èŠłçŽŻç±»ćŒ–ćˆç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’ŒćŒ»èŻç”šé€”
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
JP2022514618A (ja) 2018-12-21 2022-02-14 ăƒă‚€ă‚čă‚Żăƒ«ăƒ†ă‚Żă‚č・ăƒȘミテッド ïŒ°ïœ„ïŒïœŒïŒ‘ă«ç‰č異的ăȘäșŒç’°ćŒăƒšăƒ—ăƒăƒ‰ăƒȘガンド
SG11202106635WA (en) 2018-12-21 2021-07-29 Daiichi Sankyo Co Ltd Combination of antibody-drug conjugate and kinase inhibitor
CN113348021B (zh) 2019-01-23 2025-07-11 æ­Šç”°èŻć“ć·„äžšæ ȘćŒäŒšç€Ÿ Tyk2æŠ‘ćˆ¶ć‰‚ć’Œć…¶ç”šé€”
AU2019426113B2 (en) * 2019-01-30 2022-06-16 Felicamed Biotechnology Co., Ltd. JAK inhibitor and preparation method therefor
WO2020163431A1 (en) 2019-02-05 2020-08-13 Teva Pharmaceuticals International Gmbh Crystalline solid forms of baricitinib
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
CN113508114B (zh) * 2019-02-27 2024-03-26 ć››ć·ç§‘äŒŠćšæł°ç”Ÿç‰©ćŒ»èŻè‚Ąä»œæœ‰é™ć…Źćž ä»„æ°źæ‚çŽŻäžçƒ·èĄç”Ÿç‰©äžșæŽ»æ€§æˆćˆ†çš„ćŁæœèŻç‰©ç»„ćˆç‰©ă€ć…¶ćˆ¶ć€‡æ–čæł•ćŠç”šé€”
EP3939979A4 (en) 2019-03-14 2022-04-06 Shanghai Synergy Pharmaceutical Sciences Co., Ltd Jak kinase inhibitor, preparation method for same, and applications thereof in field of medicine
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020201753A1 (en) 2019-04-02 2020-10-08 Bicycletx Limited Bicycle toxin conjugates and uses thereof
EP3946360A4 (en) 2019-04-05 2023-05-10 Kymera Therapeutics, Inc. STAT DEGRADERS AND USES THEREOF
EP3725305A1 (en) 2019-04-17 2020-10-21 Zentiva K.S. Pharmaceutical composition containing baricitinib hydrobromide
MX2021012849A (es) * 2019-04-24 2022-02-24 Elanco Us Inc Una 7-h-pirrolo[2,3-d]pirimidina inhibidora de jak.
CN110028509B (zh) * 2019-05-27 2020-10-09 äžŠæ”·ć‹‹ć’ŒćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž 䜜äžș选择性jak2æŠ‘ćˆ¶ć‰‚çš„ćĄć’Żćč¶ć˜§ć•¶ç±»ćŒ–ćˆç‰©ă€ć…¶ćˆæˆæ–čæł•ćŠç”šé€”
KR20220034739A (ko) 2019-05-31 2022-03-18 읎쌀나 ì˜šìœœëĄœì§€, ìžìœ”íŹë ˆìŽí‹°ë“œ Tead 얔제제 및 읎의 용도
CN110256441A (zh) * 2019-06-24 2019-09-20 æ±Ÿè‹ć›è‹„ćŒ»èŻæœ‰é™ć…Źćž äž€ç§ć·Žç‘žć…‹æ›żć°Œçš„ćˆ¶ć€‡æ–čæł•
TWI862640B (zh) 2019-07-30 2024-11-21 è‹±ć•†æ‹œè„żćŻæł°ć…‹æ–Żæœ‰é™ć…Źćž 異èłȘé›™ç’°è‚œè€‡ćˆç‰©
EP3771715A1 (en) 2019-08-02 2021-02-03 Zaklady Farmaceutyczne "Polpharma" S.A. Crystalline forms of baricitinib
EP3771716A1 (en) 2019-08-02 2021-02-03 Zaklady Farmaceutyczne "Polpharma" S.A. Low hygroscopic amorphous form of baricitinib
JP2022548594A (ja) 2019-09-11 2022-11-21 ăƒ“ăƒłă‚·ă‚ąăƒ»ăƒă‚€ă‚Șă‚”ă‚€ă‚šăƒłă‚·ăƒŒă‚șăƒ»ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ïŒ”ïœ“ïœïŒ“ïŒé˜»ćźłć‰€ćŠăłăăźäœżç”š
EP4027995A4 (en) 2019-09-13 2023-08-23 Nimbus Saturn, Inc. HPK1 ANTAGONISTS AND THEIR APPLICATIONS
EP4041241A4 (en) 2019-09-27 2023-09-06 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSIS AND ASSOCIATED CONDITIONS
JP2022551649A (ja) 2019-10-10 2022-12-12 ă‚€ăƒłă‚”ă‚€ăƒˆăƒ»ă‚łăƒŒăƒăƒŹă‚€ă‚·ăƒ§ăƒł ç§»æ€ç‰‡ćŻŸćźżäž»ç—…ăźăƒă‚€ă‚ȘăƒžăƒŒă‚«ăƒŒ
US12360120B2 (en) 2019-10-10 2025-07-15 Incyte Corporation Biomarkers for graft-versus-host disease
CN110683978A (zh) * 2019-10-30 2020-01-14 è„żćź‰ćŒ»ć­Šé™ą 侀种3-腈ćŸșäșšç”ČćŸșæ°źæ‚çŽŻäžçƒ·-1-çąłé…žć”äžé…Żçš„ćˆ¶ć€‡æ–čæł•
IL292612A (en) 2019-11-01 2022-07-01 Navitor Pharm Inc Treatment methods using mtorc1 modulator
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CA3160312A1 (en) 2019-11-22 2021-05-27 Incyte Corporation Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
CA3160410A1 (en) * 2019-12-04 2021-06-10 Idorsia Pharmaceuticals Ltd Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
KR20220128345A (ko) 2019-12-05 2022-09-20 ì•„ë‚˜ìż ëŠŹì•„ 테띌퓚틱슀, ìžìœ”íŹë ˆìŽí‹°ë“œ 띌파마읎신 ìœ ì‚ŹìČŽ 및 읎의 용도
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021127190A1 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US20230107538A1 (en) 2019-12-19 2023-04-06 Liminal Biosciences Limited Cycloalkyl-containing carboxylic acids and uses thereof
KR20220151160A (ko) 2019-12-23 2022-11-14 ìčŽìŽë©”띌 쎄띌퓚틱슀 ìžìœ”íŹë ˆìŽí‹°ë“œ Smarca 분핎제 및 읎의 용도
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AU2021217172A1 (en) 2020-02-05 2022-09-22 Monash University Lipid prodrugs of neurosteroids
BR112022017727A2 (pt) 2020-03-03 2022-11-16 Pic Therapeutics Inc Inibidores de eif4e e usos dos mesmos
JP2023518423A (ja) 2020-03-19 2023-05-01 ă‚«ă‚€ăƒĄăƒ© ă‚»ăƒ©ăƒ”ăƒ„ăƒŒăƒ†ă‚Łă‚Żă‚č ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ïŒ­ïœ„ïœïŒ’ćˆ†è§Łć‰€ăŠă‚ˆăłăă‚Œă‚‰ăźäœżç”š
CN113443986A (zh) * 2020-03-27 2021-09-28 捗äșŹèŻçŸłç§‘æŠ€è‚Ąä»œæœ‰é™ć…Źćž äž€ç§ćˆæˆ3-æ°§ä»Ł-1-çŽŻäžçƒ·çŸ§é…žçš„äž­é—Žäœ“çš„ćˆ¶ć€‡æ–čæł•
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN111362853A (zh) * 2020-04-27 2020-07-03 ćź‰ćŸœć€§ć­Š 侀种3-æ°§æ‚æ°źæ‚çŽŻäžçƒ·-1-çŸ§é…žć”äžé…Żçš„ćˆ¶ć€‡æ–čæł•
CN113582901A (zh) * 2020-05-01 2021-11-02 æ”™æ±Ÿç‘žćšćˆ¶èŻæœ‰é™ć…Źćž äž€ç§æ°§ćŒ–ććș”æ°§ćŒ–é†‡ćˆ¶ć€‡é†›æˆ–é…źçš„æ–čæł•
WO2021231798A1 (en) 2020-05-13 2021-11-18 Disc Medicine, Inc. Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
US11685731B2 (en) 2020-06-02 2023-06-27 Incyte Corporation Processes of preparing a JAK1 inhibitor
TW202210483A (zh) 2020-06-03 2022-03-16 çŸŽć•†ć‡±éș„æ‹‰é†«ç™‚ć…Źćž Iraké™è§ŁćŠ‘äč‹ç”æ™¶ćž‹
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2021247897A1 (en) 2020-06-03 2021-12-09 Kymera Therapeutics, Inc. Deuterated irak degraders and uses thereof
CN111704617B (zh) * 2020-06-15 2022-08-23 昉慮ç‰čç§‘çœ—ç”Ÿç‰©ç§‘æŠ€æœ‰é™ć…Źćž äž€ç§ć°ćˆ†ć­ćŒ–ćˆç‰©
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
ES3035284T3 (en) 2020-07-02 2025-09-01 Incyte Corp Tricyclic urea compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
CN111999400B (zh) * 2020-07-15 2022-07-01 ćź‰ćŸœè”ćˆ›ç”Ÿç‰©ćŒ»èŻè‚Ąä»œæœ‰é™ć…Źćž 侀种甹hplcćˆ†çŠ»æ”‹ćźšć·Žç‘žæ›żć°ŒćŽŸæ–™èŻæ‚èŽšçš„æ–čæł•
CN111848491B (zh) * 2020-08-10 2022-06-17 çƒŸć°ć€§ć­Š 1-ç”Č酰ćŸșć’”ć”‘çš„ćˆ¶ć€‡æ–čæł•
CN111875534B (zh) * 2020-08-10 2022-06-17 çƒŸć°ć€§ć­Š 1,8-äșŒç”Č酰ćŸșć’”ć”‘çš„ćź‰ć…šé«˜æ•ˆćˆ¶ć€‡æ–čæł•
MX2023001588A (es) 2020-08-17 2023-05-03 Bicycletx Ltd Conjugados biciclo especĂ­ficos para nectina-4 y usos de estos.
MX2023002035A (es) 2020-08-18 2023-06-12 Incyte Corp Proceso e intermediarios para preparar un inhibidor de cinasa janus 1 (jak1).
EP4200300A1 (en) 2020-08-18 2023-06-28 Incyte Corporation Process and intermediates for preparing a jak inhibitor
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
AU2021364406A1 (en) 2020-10-23 2023-06-08 Elanco Us Inc. Jak inhibitors having a specific particle size distribution
JP2023546996A (ja) 2020-10-23 2023-11-08 ニンバă‚č ă‚Żăƒ­ă‚œăƒŒïŒŒ ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ïŒŁïœ”ïœïœ“ïŒ‘é˜»ćźłć‰€ăŠă‚ˆăłăăźäœżç”š
CN114437079B (zh) * 2020-10-30 2024-11-01 æ­ć·žé‚ŠéĄșćˆ¶èŻæœ‰é™ć…Źćž ćĄć’Żć˜§ć•¶äș”ć…ƒæ°źæ‚çŽŻćŒ–ćˆç‰©çš„æ™¶ćž‹
KR20230131189A (ko) 2020-12-02 2023-09-12 읎쌀나 ì˜šìœœëĄœì§€, ìžìœ”íŹë ˆìŽí‹°ë“œ Tead 얔제제 및 읎의 용도
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
KR20230118118A (ko) 2020-12-08 2023-08-10 ìžì‚ŹìŽíŠž ìœ”íŹë ˆìŽì…˜ 백반슝의 ìč˜ëŁŒë„Œ 위한 jak1 êČœëĄœ 저핎제
WO2022133420A1 (en) 2020-12-18 2022-06-23 Boehringer Ingelheim Animal Health USA Inc. Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
PH12023500015A1 (en) 2020-12-30 2024-03-11 Kymera Therapeutics Inc Irak degraders and uses thereof
EP4288430A1 (en) 2021-02-02 2023-12-13 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
EP4288427A1 (en) 2021-02-02 2023-12-13 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
CN114907354B (zh) * 2021-02-07 2024-04-09 捗äșŹçŸ„ć’ŒćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž 侀种çŁș酰èƒșç±»ć€šçŽŻćŒ–ćˆç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•äžŽç”šé€”
CN114907353A (zh) * 2021-02-09 2022-08-16 æ˜Žæ…§ćŒ»èŻïŒˆæ­ć·žïŒ‰æœ‰é™ć…Źćž äž€ç§ć‰èŻćŒ–ćˆç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œç”šé€”
US12252488B2 (en) 2021-02-12 2025-03-18 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
WO2022174269A1 (en) 2021-02-15 2022-08-18 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
IL304907A (en) 2021-02-15 2023-10-01 Kymera Therapeutics Inc Irak4 degraders and uses thereof
WO2022182839A1 (en) 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
CN118459504A (zh) * 2021-02-26 2024-08-09 捗äșŹçŸ„ć’ŒćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž äž€ç§ć·Žç‘žæ›żć°ŒèĄç”Ÿç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•äžŽç”šé€”
US11926625B2 (en) 2021-03-05 2024-03-12 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
EP4313989A4 (en) 2021-03-29 2025-03-05 Nimbus Saturn, Inc. HPK1 ANTAGONISTS AND USES THEREOF
BR112023020781A2 (pt) 2021-04-09 2023-12-19 Nimbus Clio Inc Moduladores de cbl-b e usos dos mesmos
WO2022221866A1 (en) 2021-04-16 2022-10-20 Ikena Oncology, Inc. Mek inhibitors and uses thereof
IL308216A (en) 2021-05-03 2024-01-01 Incyte Corp Jak1 pathway inhibitors for the treatment of prurigo nodularis
WO2022236058A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
WO2023288197A1 (en) * 2021-07-12 2023-01-19 Incyte Corporation Process and intermediates for preparing baricitinib
US20250041304A1 (en) 2021-07-30 2025-02-06 Eli Lilly And Company Treatment of Hand Eczema with Baricitinib
US12234231B2 (en) 2021-08-25 2025-02-25 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
CN118019739A (zh) 2021-08-25 2024-05-10 çšźć…‹ćŒ»ç–—ć…Źćž Eif4eæŠ‘ćˆ¶ć‰‚ćŠć…¶ç”šé€”
IL312397A (en) 2021-10-29 2024-06-01 Kymera Therapeutics Inc IRAK4 subunits and their synthesis
CN114373808B (zh) * 2021-11-26 2023-11-10 æ±Ÿè‹ç§‘æ„ææ–™ç§‘æŠ€æœ‰é™ć…Źćž äž€ç§é«˜æ•ˆæ™¶çĄ…ç””æ± 
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CN114149437A (zh) * 2021-12-24 2022-03-08 ćź‰ćŸœć€§ć­Š 侀种搡撯ćč¶ć˜§ć•¶äș”ć…ƒæ°źæ‚çŽŻèĄç”Ÿç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œç”šé€”
EP4472967A2 (en) 2022-01-31 2024-12-11 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
CR20240447A (es) 2022-03-17 2025-01-29 Incyte Corp Compuestos de urea tricĂ­clica como inhibidores de v617f de jak2.
WO2023194842A1 (en) 2022-04-05 2023-10-12 Unichem Laboratories Limited Substituted tricyclic compounds and their use in rheumatoid arthritis
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
TW202404581A (zh) 2022-05-25 2024-02-01 çŸŽć•†é†«è‚ŻçŽè…«ç˜€ć­žć…Źćž ïŒ­ïœ…ïœ‹æŠ‘ćˆ¶ćŠ‘ćŠć…¶ç”šé€”
CN117384163A (zh) * 2022-07-05 2024-01-12 ç››äž–æł°ç§‘ç”Ÿç‰©ćŒ»èŻæŠ€æœŻ(è‹ć·ž)è‚Ąä»œæœ‰é™ć…Źćž äž€ç§ć«ć•äșŒæ°ŸćŸșçš„ćŒ–ćˆç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œç”šé€”
AU2023317741A1 (en) 2022-08-02 2025-03-13 Liminal Biosciences Limited Aryl-triazolyl and related gpr84 antagonists and uses thereof
WO2024028363A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
AU2023317742A1 (en) 2022-08-02 2025-03-20 Liminal Biosciences Limited Substituted pyridone gpr84 antagonists and uses thereof
CN115181103B (zh) * 2022-08-16 2023-11-07 äžŠæ”·ćšæ‚Šç”Ÿç‰©ç§‘æŠ€æœ‰é™ć…Źćž äž€ç§ć·Žç‘žæ›żć°Œçš„ćˆ¶ć€‡æ–čæł•
TW202430148A (zh) 2022-11-22 2024-08-01 çŸŽć•†çšźć…‹é†«ç™‚ć…Źćž ïœ…ïŒ©ïŒŠïŒ”ïŒ„æŠ‘ćˆ¶ćŠ‘ćŠć…¶ç”šé€”
CN118255769A (zh) * 2022-12-28 2024-06-28 æ Œæ Œć·«ïŒˆç æ”·ïŒ‰ç”Ÿç‰©ç§‘æŠ€æœ‰é™ć…Źćž äž€ç§ç«‹äœ“ćŒ‚æž„äœ“çš„ćˆ¶ć€‡æ–čæł•ćŠäž­é—Žäœ“
CN120882718A (zh) * 2023-03-17 2025-10-31 挗äșŹæ™źç„șćŒ»èŻç§‘æŠ€è‚Ąä»œæœ‰é™ć…Źćž 搡撯ćč¶ć˜§ć•¶ćŒ–ćˆç‰©æˆ–ć…¶ćŻèŻç”šç›çš„ćˆ¶ć€‡æ–čæł•
CN116444529B (zh) * 2023-06-16 2023-12-05 èŻćș·äŒ—æ‹“(江苏)ćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž äž€ç§æ°˜ä»Łæ°źæ‚çŽŻäžçƒ·ç±»jakæŠ‘ćˆ¶ć‰‚ćŠć…¶ç”šé€”
WO2024264017A2 (en) 2023-06-23 2024-12-26 Kymera Therapeutics, Inc. Irak degraders and uses thereof
TW202529769A (zh) 2023-09-21 2025-08-01 æ—„ć•†æ­Šç”°è—„ć“ć·„æ„­è‚Ąä»œæœ‰é™ć…Źćž ïŒŽïœ™ïœ‹ïŒ’æŠ‘ćˆ¶ćŠ‘ćŠć…¶ç”šé€”

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3036390A1 (de) 1980-09-26 1982-05-13 Troponwerke GmbH & Co KG, 5000 Köln Neue pyrrolo-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von biologischen wirkstoffen
US4548990A (en) * 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
DE69618959T2 (de) 1995-07-05 2002-08-29 E.I. Du Pont De Nemours And Co., Wilmington Pyrimidone und ihre verwendug als fungizide
PL188959B1 (pl) 1995-07-06 2005-05-31 Novartis Ag Pirolopirymidyny i sposoby ich wytwarzania
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
CN1332743A (zh) 1998-06-04 2002-01-23 è‰Ÿćšç‰č慬揾 æŠ‘ćˆ¶ç»†èƒžçČ˜é™„æŠ—ç‚ŽćŒ–ćˆç‰©
ES2219018T3 (es) 1998-06-19 2004-11-16 Pfizer Products Inc. Compuestos de pirrolo(2,3-d)pirimidina.
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
AU5620299A (en) 1998-08-11 2000-03-06 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
AU3565999A (en) 1999-04-16 2000-11-02 Coelacanth Chemical Corporation Synthesis of azetidine derivatives
AP1905A (en) 1999-12-10 2008-10-20 Pfizer Prod Inc Pyrrolo[2,3-d] Pyrimidine Compounds.
PL209572B1 (pl) * 1999-12-24 2011-09-30 Aventis Pharma Ltd Kompozycja farmaceutyczna zawierająca podstawione azaindole, podstawione azaindole i ich farmaceutyczne zastosowania
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US6335342B1 (en) * 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
CN100548375C (zh) * 2000-06-23 2009-10-14 田èŸčäž‰è±ćˆ¶èŻæ ȘćŒäŒšç€Ÿ æŠ—è‚żç˜€äœœç”šćąžæ•ˆć‰‚
CA2412560C (en) 2000-06-26 2008-12-30 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents
US20040089753A1 (en) 2000-06-28 2004-05-13 Holland Simon Joseph Wet milling process
GB0100622D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds V111
CA2436487A1 (en) 2001-01-30 2002-08-08 Cytopia Pty Ltd. Methods of inhibiting kinases
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
JP4286134B2 (ja) 2001-08-01 2009-06-24 ăƒĄăƒ«ă‚Ż スンド ă‚«ăƒ ăƒ‘ăƒ‹ăƒŒ ă‚€ăƒłă‚łăƒŒăƒăƒŹăƒŒăƒ†ăƒƒăƒ‰ ベンă‚șă‚€ăƒŸăƒ€ă‚ŸïŒ»ïŒ”ïŒŒïŒ•âˆ’ïœ†ïŒœă‚€ă‚œă‚­ăƒŽăƒȘノンèȘ˜ć°Žäœ“
EA007983B1 (ru) 2001-09-19 2007-02-27 АĐČĐ”ĐœŃ‚ĐžŃ Đ€Đ°Ń€ĐŒĐ° ĐĄ.А. Đ˜ĐœĐŽĐŸĐ»ĐžĐ·ĐžĐœŃ‹ ĐČ ĐșачДстĐČĐ” ĐžĐœĐłĐžĐ±ĐžŃ‚ĐŸŃ€ĐŸĐČ ĐșĐžĐœĐ°Đ·ĐœŃ‹Ń… бДлĐșĐŸĐČ
CN101703509A (zh) 2001-10-30 2010-05-12 èŻșç“Šææ–Żć…Źćž 䜜äžșflt3ć—äœ“é…Șæ°šé…žæż€é…¶æŽ»æ€§æŠ‘ćˆ¶ć‰‚çš„æ˜Ÿćœąć­ąèŒçŽ èĄç”Ÿç‰©
GT200200234A (es) 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
US20040019066A1 (en) * 2002-05-06 2004-01-29 Institut Pasteur Methionine salvage pathway in bacillus
KR20100120243A (ko) * 2002-05-07 2010-11-12 플시ëč„ë‹€ 유에슀 ìžìœ”íŹë ˆìŽí‹°ë“œ ì•œëŹŒ ì „ë‹Ź 임ìč˜ë„Œ 형성하는 êł”ì •
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
JPWO2004007472A1 (ja) * 2002-07-10 2005-11-17 ć°é‡Žè–Źć“ć·„æ„­æ ȘćŒäŒšç€Ÿ ïŒŁïœƒïœ’ïŒ”ă‚ąăƒłă‚żă‚Žăƒ‹ă‚čăƒˆăŠă‚ˆăłăăźćŒ»è–Źç”šé€”
US7259161B2 (en) 2002-11-04 2007-08-21 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of JAK and other protein kinases
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
NZ539901A (en) 2002-11-26 2007-09-28 Pfizer Prod Inc Method of treatment of transplant rejection
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7407962B2 (en) 2003-02-07 2008-08-05 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors or protein kinases
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
SE0301372D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
SE0301373D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
US20050043346A1 (en) 2003-08-08 2005-02-24 Pharmacia Italia S.P.A. Pyridylpyrrole derivatives active as kinase inhibitors
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
BRPI0416909A (pt) 2003-11-25 2007-01-16 Pfizer Prod Inc método de tratamento de aterosclerose
MXPA06007002A (es) 2003-12-17 2006-08-31 Pfizer Prod Inc Compuestos de pirrolo[2,3-d]pirimidina para tratar rechazo de transplantes.
US20050187389A1 (en) * 2004-01-13 2005-08-25 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
PL2332940T3 (pl) 2004-03-30 2013-03-29 Vertex Pharma Azaindole uĆŒyteczne jako inhibitory JAK i innych kinaz biaƂkowych
CA2563699C (en) 2004-04-23 2014-03-25 Exelixis, Inc. Kinase modulators and method of use
WO2005105988A2 (en) 2004-04-28 2005-11-10 Vertex Pharmaceuticals Incorporated Crystal structure of human jak3 kinase domain complex and binding pockets thereof
US20060106020A1 (en) * 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
AU2005237254B2 (en) 2004-05-03 2010-02-04 Novartis Ag Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor
WO2005110410A2 (en) 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
PE20060426A1 (es) 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
US8039674B2 (en) * 2004-06-23 2011-10-18 Ono Pharmaceutical Co., Ltd. Compound having S1P receptor binding potency and use thereof
WO2006013114A1 (en) 2004-08-06 2006-02-09 Develogen Aktiengesellschaft Use of a timp-2 secreted protein product for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
CA2586605A1 (en) 2004-11-24 2006-06-01 Novartis Ag Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
AR054416A1 (es) * 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
MX2007009429A (es) 2005-02-03 2008-03-18 Vertex Pharma Pirrolopirimidinas utiles como inhibidores de proteinas cinasas.
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
NZ564065A (en) 2005-05-20 2011-03-31 Vertex Pharma Pyrrolopyridines useful as inhibitors of protein kinase
WO2006136823A1 (en) 2005-06-21 2006-12-28 Astex Therapeutics Limited Heterocyclic containing amines as kinase b inhibitors
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
CA2621261C (en) * 2005-09-22 2014-05-20 Incyte Corporation Azepine inhibitors of janus kinases
RU2008117151A (ru) 2005-09-30 2009-11-10 ВДртДĐșс Đ€Đ°Ń€ĐŒĐ°ŃŃŒŃŽŃ‚ĐžĐșалз Đ˜ĐœĐșĐŸŃ€ĐżĐŸŃ€Đ”ĐčтДЎ (Us) Đ”Đ”Đ°Đ·Đ°ĐżŃƒŃ€ĐžĐœŃ‹, ĐżŃ€ĐžĐłĐŸĐŽĐœŃ‹Đ” ĐČ ĐșачДстĐČĐ” ĐžĐœĐłĐžĐ±ĐžŃ‚ĐŸŃ€ĐŸĐČ ŃĐœŃƒŃ-ĐșĐžĐœĐ°Đ·
EP3184526B1 (en) * 2005-12-13 2018-10-03 Incyte Holdings Corporation Pyrrolo[2,3-d]pyrimidine derivatives as janus kinase inhibitor
EP1968568A4 (en) 2005-12-22 2011-04-13 Glaxosmithkline Llc HEMMER OF NUTS ACTIVITY
BRPI0722364A2 (pt) 2006-01-17 2011-08-16 Vertex Pharma azaindĂłis, composição farmacĂȘutica e usos dos referidos compostos
EP2001884A1 (en) 2006-04-05 2008-12-17 Vertex Pharmaceuticals, Inc. Deazapurines useful as inhibitors of janus kinases
TW200805992A (en) * 2006-07-04 2008-01-16 Benq Corp Method and apparatus for barring short message
ES2415863T3 (es) * 2006-12-22 2013-07-29 Incyte Corporation Heterociclos sustituidos como inhibidores de Janus Quinasas
MX342814B (es) * 2007-06-13 2016-10-13 Incyte Holdings Corp Sales de inhibidor de janus cinasa (r)-3-(4-7h-pirrolo[2,3-d]pirim idin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanitrilo.
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.

Also Published As

Publication number Publication date
US8158616B2 (en) 2012-04-17
PE20091712A1 (es) 2009-11-21
PL2288610T3 (pl) 2017-12-29
AU2009223640A1 (en) 2009-09-17
CN102026999B (zh) 2014-03-05
EA017218B1 (ru) 2012-10-30
SI2288610T1 (sl) 2016-11-30
PA8819201A1 (es) 2010-07-27
UY31705A1 (es) 2009-08-03
CL2009000576A1 (es) 2009-06-19
CN103788098A (zh) 2014-05-14
PE20140099A1 (es) 2014-02-06
BRPI0909040B1 (pt) 2019-10-22
US20090233903A1 (en) 2009-09-17
MY165582A (en) 2018-04-05
MA32219B1 (fr) 2011-04-01
HRP20161390T1 (hr) 2016-12-02
JP2011514909A (ja) 2011-05-12
KR101240882B1 (ko) 2013-03-11
ZA201006000B (en) 2012-01-25
DOP2013000036A (es) 2013-03-15
HUE029767T2 (en) 2017-04-28
ECSP10010475A (es) 2010-10-30
IL208023A (en) 2015-08-31
CY2017024I2 (el) 2017-11-14
NL300886I2 (nl) 2017-10-24
AU2009223640B2 (en) 2013-07-04
EA201071057A1 (ru) 2011-02-28
EP2288610B8 (en) 2016-10-12
CO6290658A2 (es) 2011-06-20
HK1149005A1 (zh) 2011-09-23
HUS1700031I1 (hu) 2017-09-28
WO2009114512A1 (en) 2009-09-17
LUC00027I2 (Direct) 2017-09-25
HN2010001761A (es) 2013-09-02
CA2718271A1 (en) 2009-09-17
PT2288610T (pt) 2016-10-17
NZ587928A (en) 2012-08-31
JP5275371B2 (ja) 2013-08-28
LTC2288610I2 (lt) 2019-02-25
LT2288610T (lt) 2016-12-12
LTPA2017023I1 (lt) 2017-08-10
SV2010003662A (es) 2011-03-17
UA101493C2 (ru) 2013-04-10
CY1118176T1 (el) 2017-06-28
KR20100121657A (ko) 2010-11-18
RS55263B1 (sr) 2017-02-28
CY2017024I1 (el) 2017-11-14
BRPI0909040A2 (Direct) 2017-09-19
DOP2010000270A (es) 2010-10-15
US20130225556A1 (en) 2013-08-29
US20120077798A1 (en) 2012-03-29
SG191660A1 (en) 2013-07-31
KR20120108042A (ko) 2012-10-04
DK2288610T3 (en) 2016-11-28
NO2017033I2 (no) 2017-07-11
MX2010010012A (es) 2010-10-20
TW200942545A (en) 2009-10-16
TWI444382B (zh) 2014-07-11
CA2718271C (en) 2014-05-06
ES2602577T3 (es) 2017-02-21
EP2288610B1 (en) 2016-08-31
JP2013155179A (ja) 2013-08-15
US8420629B2 (en) 2013-04-16
CN102026999A (zh) 2011-04-20
IL208023A0 (en) 2010-12-30
EP2288610A1 (en) 2011-03-02
TN2010000415A1 (en) 2011-12-29
LUC00027I1 (Direct) 2017-07-12
NO2017033I1 (no) 2017-07-11
BRPI0909040A8 (pt) 2017-12-12
BRPI0909040B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
AR070828A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR086198A1 (es) Inhibidores sustituidos de acetil-coa carboxilasa y composiciones farmaceuticas que los contienen
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20151602A1 (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR B(beta)2 ADRENERGICO ASI COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARINICO M3
AR090220A1 (es) Inhibidores de serina/treonina cinasa
PE20181272A1 (es) Heterociclilaminas como inhibidores de pi3k
CO6170361A2 (es) Composiciones y metodos para modular receptores de c-kit y pdgfr
AR057109A1 (es) Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis
CL2009000127A1 (es) Compuestos derivados de [indol, azaindol]-2-carboxamida sustituidos con un grupo silanilo; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso en el tratamiento del dolor, inflamacion, trastornos metabolicos, entre otras enfermedades mediadas por la modulacion del receptor trpv1.
AR046085A1 (es) Agonistas etilamino amino sustituidos del receptor beta 2 adrenergico
AR077080A1 (es) Compuestos de 2,3-dihidro-1h-indeno
ECSP11010901A (es) Compuestos de amida Ăștiles en terapia
AR084152A1 (es) Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc
PE20141352A1 (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
PE20150194A1 (es) Novedosas n-piridinil amidas ciclicas sustituidas como inhibidores de quinasa
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
AR073043A1 (es) Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras.
CO6341621A2 (es) Piperidinas arilamino y heteroarilamino sustituidas como inhibidores de glyt-1
AR081966A1 (es) Derivados aminoester de alcaloides y composicion medicinal de los mismos
AR072880A1 (es) Derivados nitrogenados de la pancratistatina
AR061433A1 (es) Compuestos de amida del acido 3-amino-tieno (2,3,b) piridina -2-carboxilico sustituido, procesos para su preparacion y usos de los mismos
AR085428A1 (es) (3r,4r)-4-ciano-3,4-difenilbutanoatos sustituidos, procedimiento para su preparacion y su uso como herbicidas y reguladores de crecimiento de plantas

Legal Events

Date Code Title Description
FG Grant, registration